



IAEA

Atoms for Peace and Development

الوكالة الدولية للطاقة الذرية

国际原子能机构

International Atomic Energy Agency

Agence internationale de l'énergie atomique

Международное агентство по атомной энергии

Organismo Internacional de Energía Atómica

National Liaison Officers /

National Coordinators

Vienna International Centre, PO Box 100, 1400 Vienna, Austria

Phone: (+43 1) 2600 • Fax: (+43 1) 26007

Email: Official.Mail@iaea.org • Internet: <https://www.iaea.org>

In reply please refer to: **SP-RER6044-2602023**

Dial directly to extension: (+43 1) 2600-25804

2026-07-06

Subject: EANM/ESMIT Training Course on Prostate Cancer Theranostics, 24– 25 September 2026, Vienna, Austria

Dear National Liaison Officer / National Coordinator,

I am pleased to inform you that the International Atomic Energy Agency (IAEA) will sponsor participants to attend *EANM/ESMIT Training Course on Prostate Cancer Theranostics* within the framework of the IAEA technical cooperation project **RER6044, "Strengthening Nuclear Medicine Diagnostic Imaging and Therapeutic Services in Europe and Central Asia"**.

The attached information sheet provides further details. Selection of participants will be in accordance with IAEA procedures. Member States are strongly encouraged to identify women participants.

We would appreciate receiving your country's nominations **by 25 July 2026** through the IAEA's InTouch+ platform (<https://Intouchplus.iaea.org>). Please be advised that late nominations or replacements of participants after the closing date for nominations will not be accepted.

We look forward to receiving your early response.

Yours sincerely,

Sibel Unlu

Programme Management Officer

Division for Europe

Department of Technical Cooperation

Enclosure: Information Sheet

**TC Sponsored Participation at the training course on
Prostate Cancer Theranostics**

Event Number	SP-RER6044-2602023
Event Title	EANM/ESMIT Training Course on Prostate Cancer Theranostics
Location	Vienna, Austria
Date	24 to 25 September 2026
Nomination Deadline	24 July 2026
Event Information	Radiolabelled prostate-specific membrane antigen (PSMA) is increasingly used for the diagnosis (i.e., staging and restaging) and treatment of patients with prostate cancer. Radionuclide PSMA therapy is a useful new treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC) and potentially also in patients with hormone-sensitive prostate cancer. The course will cover the spectrum of radiolabelled PSMA tracers and techniques related to PSMA imaging, from diagnosis to therapy, with lectures, interactive case discussions, and relevant information for clinical practice.
Organizer	European School of Multimodality Imaging & Therapy (ESMIT) Link: https://esmit.eanm.org/event/prostate-cancer-theranostics-2/
Selection Criteria	General nuclear medicine specialists, residents, radiologists and healthcare specialists who want to update their knowledge on molecular imaging of prostate cancer and radiolabelled PSMA therapy (theranostics).